These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32524319)

  • 1. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
    Lemech C; Woodward N; Chan N; Mortimer J; Naumovski L; Nuthalapati S; Tong B; Jiang F; Ansell P; Ratajczak CK; Sachdev J
    Invest New Drugs; 2020 Dec; 38(6):1815-1825. PubMed ID: 32524319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
    Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW
    Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
    Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
    Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
    Anderson MG; Zhang Q; Rodriguez LE; Hecquet CM; Donawho CK; Ansell PJ; Reilly EB
    BMC Cancer; 2021 Jun; 21(1):681. PubMed ID: 34107902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
    LoRusso P; Ratain MJ; Doi T; Rasco DW; de Jonge MJA; Moreno V; Carneiro BA; Devriese LA; Petrich A; Modi D; Morgan-Lappe S; Nuthalapati S; Motwani M; Dunbar M; Glasgow J; Medeiros BC; Calvo E
    Invest New Drugs; 2022 Aug; 40(4):762-772. PubMed ID: 35467243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
    King GT; Eaton KD; Beagle BR; Zopf CJ; Wong GY; Krupka HI; Hua SY; Messersmith WA; El-Khoueiry AB
    Invest New Drugs; 2018 Oct; 36(5):836-847. PubMed ID: 29333575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
    Demetri GD; Luke JJ; Hollebecque A; Powderly JD; Spira AI; Subbiah V; Naumovski L; Chen C; Fang H; Lai DW; Yue H; Polepally AR; Purcell JW; Robinson R; Sharma P; Allison JP; Tolcher A; Villalobos VM
    Clin Cancer Res; 2021 Jul; 27(13):3556-3566. PubMed ID: 33820780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
    J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
    Hamilton E; O'Malley DM; O'Cearbhaill R; Cristea M; Fleming GF; Tariq B; Fong A; French D; Rossi M; Brickman D; Moore K
    Gynecol Oncol; 2020 Sep; 158(3):640-645. PubMed ID: 32513564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
    Piha-Paul SA; Sachdev JC; Barve M; LoRusso P; Szmulewitz R; Patel SP; Lara PN; Chen X; Hu B; Freise KJ; Modi D; Sood A; Hutti JE; Wolff J; O'Neil BH
    Clin Cancer Res; 2019 Nov; 25(21):6309-6319. PubMed ID: 31420359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
    Vij R; Nath R; Afar DEH; Mateos MV; Berdeja JG; Raab MS; Guenther A; Martínez-López J; Jakubowiak AJ; Leleu X; Weisel K; Wong S; Gulbranson S; Sheridan JP; Reddy A; Paiva B; Singhal A; San-Miguel JF; Moreau P
    Clin Cancer Res; 2020 May; 26(10):2308-2317. PubMed ID: 31969330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
    Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
    Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
    Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
    Carneiro BA; Papadopoulos KP; Strickler JH; Lassman AB; Waqar SN; Chae YK; Patel JD; Shacham-Shmueli E; Kelly K; Khasraw M; Bestvina CM; Merrell R; Huang K; Atluri H; Ansell P; Li R; Jin J; Anderson MG; Reilly EB; Morrison-Thiele G; Patel K; Robinson RR; Aristide MRN; Gan HK
    Neurooncol Adv; 2023; 5(1):vdac183. PubMed ID: 36814898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
    Kollmannsberger C; Britten CD; Olszanski AJ; Walker JA; Zang W; Willard MD; Radtke DB; Farrington DL; Bell-McGuinn KM; Patnaik A
    Invest New Drugs; 2021 Dec; 39(6):1613-1623. PubMed ID: 34264412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.